Vectivbio | YesPress

Browse all tags

ceo2908 saas2409 ai1721 fintech1451 founder1251 b2b1071 b2b saas885 san francisco822 co-founder814 san-francisco796 y combinator768 startup729 machine learning663 enterprise software623 stanford603 series a590 venture capital576 biotech543 cybersecurity532 healthtech479 new york startup469 enterprise-software445 ai agents442 generative ai436 digital health434 silicon-valley389 agentic ai388 d2c384 silicon valley380 ecommerce378 machine-learning373 startup founder360 california351 entrepreneur350 new york347 venture-capital340 edtech338 climate tech327 newsletter321 mit302 proptech301 robotics292 y-combinator279 san francisco startup278 series b270 enterprise ai269 developer tools264 computer vision254 oncology252 open-source247 series-a243 harvard242 sustainability240 supply chain232 enterprise230 iot229 biotechnology223 compliance222 workflow automation221 telehealth217 founder ceo216 healthcare212 insurtech211 developer-tools210 blockchain209 devops208 medical devices206 series-b206 forbes 30 under 30194 llm192 logistics190 uc berkeley189 author188 deep tech187 clean energy186 generative-ai185 web3184 a16z183 cloud183 drug discovery182 life sciences176 artificial intelligence175 no-code175 b2c173 manufacturing173 payments170 general partner169 healthcare ai169 serial entrepreneur167 seed funding164 open source162 crm161 podcast160 hardware159 unicorn158 digital transformation156 predictive analytics152 automation151 crypto150 infrastructure150

Often tagged with

aditya venugopal1 alentis therapeutics1 chief business officer1 biotech executive1 business development1 corporate development1 life sciences1 claudin-11 fibrosis1 oncology1 antibody-drug conjugates1 rare diseases1 immunology1 ph.d.1

Tagged: vectivbio

1 result

Sort

Executive · Operator · Scientist

Aditya Venugopal

Aditya Venugopal is the Chief Business Officer of Alentis Therapeutics, a clinical-stage Swiss biotech chasing first-in-class therapies aimed at claudin-1 for fibrosis and cancer. An immunologist turned dealmaker, he spent 15-plus years moving between the lab bench and the negotiating table: a Ph.D. in immunology from Weill Cornell, seven years in strategic life-science consulting, then senior roles at Intercept, VectivBio and Versanis Bio. He has a habit of being in the room when companies get acquired - VectivBio went to Ironwood, Versanis went to Eli Lilly - and he reunited with CEO Mark Pruzanski at Alentis after first partnering with him at Intercept.

aditya venugopal · alentis therapeuticsRead →